NK cells from AML patients typically express more NCRs/NKG2D/DNAM-1, down-regulated NKG2A/iKIRs (113) and the ability of NK cells secreting IFN-γ is significantly reduced which may limit their ability to recognize and clear AML cells and patients with NK cell spectrum defects increased recurrence risk (p = 0.03) without regard for their cytogenetic classification (125). Here, KLRK1 is linked to acute myeloid leukemia.